Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials

Andrew Blauvelt; Mark Lebwohl; Richard G. Langley; Katelyn Rowland; Ya Wen Yang; Daphne Chan; Megan Miller; Yin You; Jenny Yu; Diamant Thaҫi; Peter Foley; Kim A. Papp

doi:10.1016/j.jaad.2023.03.035

Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials

Andrew Blauvelt, Mark Lebwohl, Richard G. Langley, Katelyn Rowland, Ya Wen Yang, Daphne Chan, Megan Miller, Yin You, Jenny Yu, Diamant Thaҫi, Peter Foley, Kim A. Papp

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Original language	English
Pages (from-to)	274-282
Number of pages	9
Journal	Journal of the American Academy of Dermatology
Volume	89
Issue number	2
DOIs	https://doi.org/10.1016/j.jaad.2023.03.035
Publication status	Published - Aug 2023
Externally published	Yes

ASJC Scopus Subject Areas

Dermatology

Keywords

guselkumab
malignancy
nonmelanoma skin cancer
psoriasis
safety
tumor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jaad.2023.03.035

Cite this

Blauvelt, A., Lebwohl, M., Langley, R. G., Rowland, K., Yang, Y. W., Chan, D., Miller, M., You, Y., Yu, J., Thaҫi, D., Foley, P., & Papp, K. A. (2023). Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials. Journal of the American Academy of Dermatology, 89(2), 274-282. https://doi.org/10.1016/j.jaad.2023.03.035

Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials. / Blauvelt, Andrew; Lebwohl, Mark; Langley, Richard G. et al.
In: Journal of the American Academy of Dermatology, Vol. 89, No. 2, 08.2023, p. 274-282.

Research output: Contribution to journal › Article › peer-review

Blauvelt, A, Lebwohl, M, Langley, RG, Rowland, K, Yang, YW, Chan, D, Miller, M, You, Y, Yu, J, Thaҫi, D, Foley, P & Papp, KA 2023, 'Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials', Journal of the American Academy of Dermatology, vol. 89, no. 2, pp. 274-282. https://doi.org/10.1016/j.jaad.2023.03.035

@article{66349e5788504224a8c191d9fa90113c,

title = "Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials",

keywords = "guselkumab, malignancy, nonmelanoma skin cancer, psoriasis, safety, tumor",

author = "Andrew Blauvelt and Mark Lebwohl and Langley, {Richard G.} and Katelyn Rowland and Yang, {Ya Wen} and Daphne Chan and Megan Miller and Yin You and Jenny Yu and Diamant Thaҫi and Peter Foley and Papp, {Kim A.}",

note = "Publisher Copyright: {\textcopyright} 2023 American Academy of Dermatology, Inc.",

year = "2023",

month = aug,

doi = "10.1016/j.jaad.2023.03.035",

language = "English",

volume = "89",

pages = "274--282",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "2",

}

TY - JOUR

T1 - Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab

T2 - Pooled results from the VOYAGE 1 and VOYAGE 2 trials

AU - Blauvelt, Andrew

AU - Lebwohl, Mark

AU - Langley, Richard G.

AU - Rowland, Katelyn

AU - Yang, Ya Wen

AU - Chan, Daphne

AU - Miller, Megan

AU - You, Yin

AU - Yu, Jenny

AU - Thaҫi, Diamant

AU - Foley, Peter

AU - Papp, Kim A.

PY - 2023/8

Y1 - 2023/8

KW - guselkumab

KW - malignancy

KW - nonmelanoma skin cancer

KW - psoriasis

KW - safety

KW - tumor

UR - http://www.scopus.com/inward/record.url?scp=85153961239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85153961239&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2023.03.035

DO - 10.1016/j.jaad.2023.03.035

M3 - Article

C2 - 37019386

AN - SCOPUS:85153961239

SN - 0190-9622

VL - 89

SP - 274

EP - 282

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 2

ER -

Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials

ASJC Scopus Subject Areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this